Personalis, Inc. entered into a merger agreement with Tempus AI, Inc. to be acquired in a transaction that will result in the company's survival as a wholly-owned subsidiary of Tempus. The consideration for stockholders will consist of a combination of stock and cash, with a potential cash election by Tempus for up to 50% of the outstanding shares at $16.25 per share. Personalis, Inc. operates in the healthcare and genomics industry, providing personalized medicine solutions.
